---
title: "蘇州昊帆生物股份有限公司 (301393.SZ)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/301393.SZ.md"
symbol: "301393.SZ"
name: "蘇州昊帆生物股份有限公司"
industry: "制藥"
---

# 蘇州昊帆生物股份有限公司 (301393.SZ)

| Item | Detail |
|------|--------|
| Industry | 制藥 |
| Location | 滬深市場 |
| Website | [www.highfine.com](https://www.highfine.com) |

## Company Profile

公司成立于 2003 年，是一家為全球醫藥研發及原料藥生產企業提供特色原料的高新技術企業。致力于服務新藥研發的前端進程，為創新藥物研發和藥品生產提供快速、精準的配套服務。通過緊跟全球創新藥研發方向，貼近國內外 CRO、CDMO 公司的市場需求，已成為業內領先的特色功能化學品供應商。公司專注于多肽合成試劑的研發、生產與銷售。主要產品有：多肽合成試劑、通用型分子砌塊、蛋白質試劑、脂質體與脂質納米粒藥用試劑。企業榮譽：蘇州高新區瞪羚企業、2018 年度高新區科技創新先進單位、專精特新中小企業等。

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-21T04:30:10.000Z

**Overall: B (0.34)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 49 / 222 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 35.11% |  |
| Net Profit YoY | 17.65% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 2.42 |  |
| Dividend Ratio | 0.75% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 5.69B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 558.41M |  |


**Multi Score**: B

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 5.97% | C |
| Profit Margin | 24.53% | A |
| Gross Margin | 36.27% | C |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 35.11% | A |
| Net Profit YoY | 17.65% | B |
| Total Assets YoY | 9.15% | B |
| Net Assets YoY | 4.79% | C |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 407.73% | C |
| OCF YoY | 35.11% | A |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.23 | D |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 7.86% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 蘇州昊帆生物股份有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "5.97%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "24.53%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "36.27%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "35.11%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "17.65%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "9.15%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "4.79%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "407.73%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "35.11%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.23",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "7.86%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 艾力斯 (SH.688578) | A | A | B | A | B | A |
| 02 | 興齊眼藥 (SZ.300573) | A | A | A | B | B | A |
| 03 | 恆瑞醫藥 (SH.600276) | A | B | C | A | B | B |
| 04 | 雲南白藥 (SZ.000538) | B | C | B | B | C | B |
| 05 | 信立泰 (SZ.002294) | B | B | C | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 41.52 | 95/222 | 43.24 | 40.78 | 38.77 |
| PB | 2.42 | 100/222 | 2.57 | 2.42 | 2.27 |
| PS (TTM) | 10.18 | 183/222 | 12.03 | 11.05 | 10.27 |
| Dividend Yield | 0.75% | 115/222 | 0.79% | 0.74% | 0.70% |

## Institutional View

### Analyst Rating Distribution

> As of 2025-07-01T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 52.65 |
| Highest Target | 60.00 |
| Lowest Target | 60.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/301393.SZ/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/301393.SZ/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/301393.SZ/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.